Moxifloxacin Fresenius Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Fresenius Kabi, is a fluoroquinolone antibiotic presented as a solution for injection for intravenous use. It treats severe community‑acquired bacterial pneumonia, complicated intra‑abdominal infections, and complicated skin and skin‑structure infections in adult patients.

GNH USA supplies Moxifloxacin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide.

Moxifloxacin is a fluoroquinolone antibacterial used for serious bacterial infections affecting the respiratory, abdominal, and skin compartments.

- Severe community‑acquired bacterial pneumonia: provides rapid bacterial eradication and improves clinical outcomes in adults. - Complicated intra‑abdominal infections: achieves effective coverage of Gram‑negative, Gram‑positive and anaerobic pathogens. - Complicated skin and skin‑structure infections: delivers bactericidal activity against common skin pathogens, facilitating recovery.

Moxifloxacin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or swelling, especially in the Achilles. - QT interval prolongation: cardiac rhythm disturbances that may lead to arrhythmia. - Severe hypersensitivity reactions: anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.

When prescribing Moxifloxacin, clinicians should consider several safety and handling precautions.

- Renal impairment: adjust therapy and monitor renal function. - Hepatic dysfunction: use with caution in patients with liver disease. - Concomitant QT‑prolonging drugs: avoid or monitor ECG for arrhythmia risk. - History of tendon disorders: discontinue if tendon pain or inflammation occurs. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, and retain in original packaging.

Moxifloxacin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption; separate administration by at least 2 hours. - Warfarin: may increase INR; monitor coagulation parameters closely. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - Theophylline: may raise plasma levels; observe for toxicity. - Cyclosporine: potential increase in cyclosporine concentrations. - Oral contraceptives: possible reduction in effectiveness; advise additional contraceptive measures.